Allergic Rhinitis Due to AllergensPhase 2NCT07556393
Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis
A Phase 2 study testing INI-2004 in people with Allergic Rhinitis Due to Allergens and Rhinitis Allergic, run by Inimmune Corporation at 1 site in Canada.
Trial summary
The purpose of this trial is to see how well an experimental nasal spray, called INI-2004, works for those with allergy symptoms to ragweed. This nasal spray will compare how well 500mcg of INI-2004, given once per week for 4 weeks, works at reducing ragweed allergy symptoms in an Environmental Exposure Unit (EEU)… Read more about this study
- Who is it for?
- Ages 18 to 64 years
- Conditions the study is for
- Allergic Rhinitis Due to Allergens, Rhinitis Allergic, Allergic Rhinitis
- What is being tested?
- INI-2004
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 78 participants
- Where
- 1 siteCanada
- Study dates
- 19 Jan 2026to 23 Apr 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Must have given valid written informed consent, before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
- Healthy male or female, aged between 18 and 64 years, inclusive at screening.
- Minimum 12-month history of ragweed-induced AR requiring pharmacotherapy (self-reported history accepted), history of or current positive ragweed skin prick test reaction (≥ 5mm greater than the diluent) at SV1, and a TNSS score of ≥ 6 at 2 timepoints during the SV2 ragweed allergen EEU challenge, including a "congestion" score of ≥ 2 at ≥ 1 time point.
- Body mass index (BMI) of 17 to 39 kg/m2, inclusive, at screening. Subjects with BMI > 39 kg/m2 may be included with permission of the Sponsor.
- Participant is medically healthy (in the opinion of the PI [or delegate]), as determined by medical history and without clinically significant abnormalities including:
- Physical examination without any additional clinically relevant findings
Show all 18Show fewer
- Vital signs (pulse, blood pressure, respiratory rate, temperature) without clinically significant abnormalities, in the opinion of the PI (or delegate).
- Electrocardiogram without clinically significant abnormality at screening including QT interval corrected for Fredericia (QTcF) ≤ 450 msec for male subjects and ≤ 470 msec for female subjects. The ECG may be repeated if technically unsatisfactory (e.g. artifact) or otherwise thought not to be representative, at the discretion of the Investigator.
- No clinically significant findings in serum chemistry, hematology or urinalysis as judged by the PI (or delegate).
- Female participants must be of non-child-bearing potential i.e., surgically sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the screening visit) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone (FSH) level consistent with postmenopausal status, per local laboratory guidelines), or, if of child-bearing potential*:
- Must have a negative serum pregnancy test at the screening visit 1, and a negative urine pregnancy test at screening visit 2 and prior to all dose and EEU exposure visits.
- Must agree not to donate ova or attempt to become pregnant from the time of signing consent until at least 30 days after the last dose of study drug.
- If not exclusively in a same-sex relationship or abstinent as a committed lifestyle, must agree to use adequate contraception (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception (See Appendix 2) from one month prior to dose administration until at least 30 days after the last dose of study drug).
- Women who have been surgically sterilized through tubal ligation are permitted to participate, if they agree to use an additional barrier method of contraception from one month prior to the first dose of study drug, until at least 30 days after the last dose of study drug.
- Male participants must:
- Agree not to donate sperm from the time of signing consent until at least 90 days after the last dose of study drug.
- If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception (defined as use of a condom plus a highly effective method of contraception from the time of signing consent until at least 90 days after the last dose of study drug).
- Willing and able to comply with all scheduled visits, treatment plans, laboratory tests and other study procedures.
Who cannot join
- Hypersensitivity or other clinically significant reaction to the study drug or its active ingredients.
- History of perennial allergic rhinitis which may confound study results.
- Ragweed targeted allergy immunotherapy within five years of screening.
- Expected travel to an area with potential environmental ragweed exposure within 7 days of SV2 through Day 38.
- History of any clinically relevant or unstable disorder which, in the opinion of the PI (or delegate) would make implementation of the protocol or interpretation of study results difficult, or that would put the subject at risk by participating in the study, including uncontrolled cardiovascular, hematologic, pulmonary, hepatic, renal, gastrointestinal, connective tissue disease, immunologic, uncontrolled endocrine/metabolic, oncologic (within the last 5 years), neurologic, and psychiatric diseases. Note: a history of fully resolved childhood asthma is not exclusionary; history of cholecystectomy is not exclusionary; history of anxiety and/or depression is permitted provided symptoms are controlled on or off approved concomitant medication for at least 6 months prior to SV1. Local malignancies with complete surgical resection (e.g. basal cell carcinoma, cervical cancer-in-situ) are not exclusionary.
- Asthma that requires regular pharmacotherapy, is expected to require regular pharmacotherapy during study participation, or that is expected to be exacerbated by ragweed EEU challenge. Note: PRN pharmacotherapy for asthma is permitted, as long as there has been no use within 14 days prior to the first dose of study drug on Day 0. Participants must refrain from use during the study, unless medically necessary.
Show all 23Show fewer
- Currently experiencing symptomatic perennial rhinitis requiring medication as per PI (or delegate) judgement.
- Use of oral or systemic steroids within 28 days of SV2, oral anti-histamines within 14 days of SV2, and intranasal medications, or any prescription or over-the-counter medication within 7 days prior to SV2 or expected use during study conduct from 7 days before Day 0 through Day 38, that would affect TNSS scores, in the opinion of the PI (or delegate). Topical steroids are allowable.
- Any clinically relevant structural nasal abnormalities that may affect distribution of study drug in the nasopharynx i.e., nasal septal perforation, nasal polyps, other nasal malformations or history of frequent nosebleeds. Note: fully resolved abnormalities/malformations (e.g., via rhinoplasty) are permitted.
- Upper respiratory tract infection or upper respiratory tract infection symptoms at SV2 that in the opinion of the PI (or delegate) affect TNSS score and/or other patients' safety.
- Other active infection requiring systemic antibiotic, antifungal, or antiviral medication within 14 days prior to first dose of study drug (Day 0), unless such treatment will not interfere with the objectives of the study, in the opinion of the PI (or delegate) and with Sponsor approval.
- Concurrent enrolment in another clinical study, or participation in another clinical study within 30 days prior to the first dose of study drug on Day 0.
- Regular consumption of >14 standard alcoholic drinks/week where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc/Vol], 100 mL wine [12% Alc/Vol], 30 mL spirit [40% Alc/Vol]).
- History of opioid abuse within 3 months of Screening, or the requirement for daily use of opioids for more than 7 days within one month of Screening. Definition of abuse will be as per PI or delegate's judgement.
- Current history of drug abuse. Note: UDS testing at SV1 with positive results that result from prescription products used appropriately, that do not represent a history of abuse, are not exclusionary. Repeat assessment is permitted at the discretion of the PI (or delegate) in the instance of positive results. "False positive" results from acceptable products may be disregarded at the discretion of the PI (or delegate). At the discretion of the PI (or delegate), a positive result for delta-9-tetrahydrocannabinol (THC) may not be exclusionary, however participants are not permitted to use combustible or other cannabinoid products within 24 hours prior to each visit SV2 through Day 38
- Current use of combustible or chewed tobacco products greater than the equivalent of 10 cigarettes per day, or unwilling to comply with restriction or abstention from all tobacco products 12 hours before each dose of study drug and each EEU session.
- Participant is breastfeeding or pregnant or planning to breastfeed or become pregnant during the study.
- Known substance abuse or medical, psychological, or social conditions that, in the opinion of the PI (or delegate), may interfere with the participants inclusion in the clinical study or evaluation of the clinical study results.
- History of or current infection with Hepatitis B, Hepatitis C, or HIV.
- Participant has donated blood or blood products within the following timeframe prior to first dose administration (Day 0):
- Blood = 60 days; plasma = 14 days
- Participant plans to travel to an area with known environmental ragweed exposures at any time during study participation (from SV1 through to Day 38).
- Any other condition or prior therapy that in the opinion of the PI (or delegate) would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
Trial locations and contacts
1 site in 1 country.
Canada1 site
Kingston Health Sciences Centre- KGH site
Kingston, Ontario, K7L2V7
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Environmental Exposure Unit Trial of Intranasal INI-2004 in Subjects With Ragweed-induced Allergic Rhinitis
The purpose of this trial is to see how well an experimental nasal spray, called INI-2004, works for those with allergy symptoms to ragweed. This nasal spray will compare how well 500mcg of INI-2004, given once per week for 4 weeks, works at reducing ragweed allergy symptoms in an Environmental Exposure Unit (EEU), compared to placebo.
- Being tested
- INI-2004, Placebo
- Keywords
- Ragweed, Allergic, Rhinitis
- Medical subject headings
- Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Rhinitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
INI-2004Drug
Toll-like receptor [TLR]4 agonist liposomal formulation
PlaceboOther
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Subjects receive a 500 μg dose of INI-2004 | Active comparator | Administered as four weekly intranasal doses Receives: Drug: INI-2004 |
| Subjects receive dose of placebo | Placebo comparator | Administered as four weekly intranasal doses Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of incidence, severity and relationship of treatment-emergent adverse events (TEAEs), leading to discontinuation of study treatment
Assessment of adverse events (AEs) to determine the safety and tolerability of INI-2004 following four weekly doses
Measured: Baseline (SV2) vs Day 24
Calculate the change from baseline (SV2) vs D24 in Total Nasal Symptom Score (TNSS) during the chamber exposure (AUC0-180) for all subjects
To evaluate the efficacy of INI-2004 compared with placebo by assessing change in the Area Under the Curve (AUC) of the Total Nasal Symptom Score (TNSS)
Measured: Baseline (SV2) vs Day 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start19 Jan 2026
- Primary completion23 Apr 2026
- Study completion23 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Allergic Rhinitis Due to AllergensStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 78 participants (actual)
Sponsor and investigators
- Lead sponsor
- Inimmune Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Rho, Inc.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07556393
- Sponsor's protocol ID
- INI-2004-102
- Status last verified
- Apr 2026
- First submitted
- 15 Jan 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Environmental Exposure Unit Trial of Intranasal INI-2004 in Subjects With Ragweed-induced Allergic Rhinitis
- ClinicalTrials.gov ID
- NCT07556393
- Acronym / sponsor ID
- INI-2004-102
- Keywords
- Ragweed, Allergic, Rhinitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 78 participants (actual)
- Lead sponsor
- Inimmune CorporationIndustry (pharma, biotech, devices)
- Collaborators
- Rho, Inc.
- Study start
- 19 Jan 2026 (actual)
- Primary completion
- 23 Apr 2026 (actual)
- Study completion
- 23 Apr 2026 (actual)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this trial is to see how well an experimental nasal spray, called INI-2004, works for those with allergy symptoms to ragweed. This nasal spray will compare how well 500mcg of INI-2004, given once per week for 4 weeks, works at reducing ragweed allergy symptoms in an Environmental Exposure Unit (EEU), compared to placebo.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Subjects receive a 500 μg dose of INI-2004 | Active comparator | Drug: INI-2004Administered as four weekly intranasal doses |
| Subjects receive dose of placebo | Placebo comparator | Other: PlaceboAdministered as four weekly intranasal doses |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (18 listed)
- Must have given valid written informed consent, before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
- Healthy male or female, aged between 18 and 64 years, inclusive at screening.
- Minimum 12-month history of ragweed-induced AR requiring pharmacotherapy (self-reported history accepted), history of or current positive ragweed skin prick test reaction (≥ 5mm greater than the diluent) at SV1, and a TNSS score of ≥ 6 at 2 timepoints during the SV2 ragweed allergen EEU challenge, including a "congestion" score of ≥ 2 at ≥ 1 time point.
- Body mass index (BMI) of 17 to 39 kg/m2, inclusive, at screening. Subjects with BMI > 39 kg/m2 may be included with permission of the Sponsor.
- Participant is medically healthy (in the opinion of the PI [or delegate]), as determined by medical history and without clinically significant abnormalities including:
Key exclusion criteria (23 listed)
- Hypersensitivity or other clinically significant reaction to the study drug or its active ingredients.
- History of perennial allergic rhinitis which may confound study results.
- Ragweed targeted allergy immunotherapy within five years of screening.
- Expected travel to an area with potential environmental ragweed exposure within 7 days of SV2 through Day 38.
- History of any clinically relevant or unstable disorder which, in the opinion of the PI (or delegate) would make implementation of the protocol or interpretation of study results difficult, or that would put the subject at risk by participating in the study, including uncontrolled cardiovascular, hematologic, pulmonary, hepatic, renal, gastrointestinal, connective tissue disease, immunologic, uncontrolled endocrine/metabolic, oncologic (within the last 5 years), neurologic, and psychiatric diseases. Note: a history of fully resolved childhood asthma is not exclusionary; history of cholecystectomy is not exclusionary; history of anxiety and/or depression is permitted provided symptoms are controlled on or off approved concomitant medication for at least 6 months prior to SV1. Local malignancies with complete surgical resection (e.g. basal cell carcinoma, cervical cancer-in-situ) are not exclusionary.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| INI-2004Toll-like receptor [TLR]4 agonist liposomal formulation | Drug | Subjects receive a 500 μg dose of INI-2004 |
| PlaceboPlacebo | Other | Subjects receive dose of placebo |
Primary outcome
Assessment of incidence, severity and relationship of treatment-emergent adverse events (TEAEs), leading to discontinuation of study treatment
Time frame: Baseline (SV2) vs Day 24
Assessment of adverse events (AEs) to determine the safety and tolerability of INI-2004 following four weekly doses
Calculate the change from baseline (SV2) vs D24 in Total Nasal Symptom Score (TNSS) during the chamber exposure (AUC0-180) for all subjects
Time frame: Baseline (SV2) vs Day 24
To evaluate the efficacy of INI-2004 compared with placebo by assessing change in the Area Under the Curve (AUC) of the Total Nasal Symptom Score (TNSS)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
Related trials for Allergic Rhinitis Due to Allergens
Not yet recruitingObservational study
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
Conjunctivitis Allergic
RecruitingObservational study
The Efficacy of Specific Immunotherapy Guided by Component-Resolved Diagnosis for Dust Mite Allergens in Chinese Pediatric Patients With Rhinitis and/or Asthma
Allergic Rhinitis Due to House Dust Mite
Not yet recruitingObservational study
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing INI-2004 in people with Allergic Rhinitis Due to Allergens and Rhinitis Allergic, run by Inimmune Corporation at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of incidence, severity and relationship of treatment-emergent adverse events (TEAEs), leading to discontinuation of study treatment (time frame: Baseline (SV2) vs Day 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.